Last 12 months
Inside the activity.
0 purchase rows · 3 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2013 Filed Mar 28, 2013 21:29 UTC |
WILENSKY GAIL RDirector
|
GrantCommon Stock | 52 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-018865 · doc4.xml · nonDerivative · entry 1 WILENSKY GAIL R · CIK 0001018538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,525 F1 · shares: Represents dividend equivalents paid on vested deferred stock units. The dividend equivalents are immediately vested but must be retained by the director until the director's completion of service on the Board. Read SEC document |
| March 19, 2013 Filed Mar 20, 2013 20:22 UTC |
Sweere LoriEVP, Human Capital
|
SaleCommon Stock | 11,038 | $55.20 | $609,243.51 |
DisclosureSEC source: 0001209191-13-017735 · doc4.xml · nonDerivative · entry 1 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,412.8754 F1 · price: This transaction was executed in multiple trades ranging from $55.11 to $55.225 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 08, 2013 Filed Mar 11, 2013 21:19 UTC |
RANGEN ERIC SSr VP & Chief Acctg Officer
|
SaleCommon Stock | 33,336 | $54.00 | $1,800,187.34 |
DisclosureSEC source: 0001209191-13-015638 · doc4.xml · nonDerivative · entry 1 RANGEN ERIC S · CIK 0001175737 · Sr VP & Chief Acctg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,427.555 F1 · price: This transaction was executed in multiple trades ranging from $54.00 to $54.015 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
SaleCommon Stock | 2,561 | $53.18 | $136,201.41 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 10 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,819.5533 F2 · price: This transaction was executed in multiple trades ranging from $52.91 to $53.46 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
SaleCommon Stock | 3,880 | $53.18 | $206,349.65 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 7 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,500.5533 F2 · price: This transaction was executed in multiple trades ranging from $52.91 to $53.46 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
SaleCommon Stock | 6,650 | $53.18 | $353,666.29 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 4 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,500.5533 F2 · price: This transaction was executed in multiple trades ranging from $52.91 to $53.46 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2013 Filed Feb 27, 2013 23:02 UTC |
RENFRO LARRY CEVP, UHG and CEO, Optum
|
SaleCommon Stock | 84,114 | $52.89 | $4,448,436.18 |
DisclosureSEC source: 0001209191-13-012162 · doc4.xml · nonDerivative · entry 1 RENFRO LARRY C · CIK 0001235046 · EVP, UHG and CEO, Optum 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,060.043 F1 · price: This transaction was executed in multiple trades ranging from $52.71 to $53.14 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Exercise / conversionStock Appreciation Rights · Derivative | 19,006 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · derivative · entry 13 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,006 Underlying: Common Stock · 19,006 shares Expires 2020-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock appreciation rights vest at a rate of 25% annually on February 9 from the years 2011 through 2014. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Exercise / conversionStock Appreciation Rights · Derivative | 19,006 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · derivative · entry 12 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,012 Underlying: Common Stock · 19,006 shares Expires 2020-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock appreciation rights vest at a rate of 25% annually on February 9 from the years 2011 through 2014. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Exercise / conversionStock Appreciation Rights · Derivative | 28,280 | $0.00 Strike: $29.74 | $0.00 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · derivative · entry 11 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,280 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock appreciation rights vested at a rate of 25% annually on February 3 from the years 2010 through 2013. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Tax withholdingCommon Stock | 15,126 | $54.47 | $823,913.22 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 9 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,380.5533 Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Exercise / conversionCommon Stock | 19,006 | $33.00 | $627,198.00 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 8 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,506.5533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Tax withholdingCommon Stock | 15,126 | $54.47 | $823,913.22 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 6 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,380.5533 Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Exercise / conversionCommon Stock | 19,006 | $33.00 | $627,198.00 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 5 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,506.5533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Tax withholdingCommon Stock | 21,630 | $54.47 | $1,178,186.10 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 3 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,150.5533 Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Exercise / conversionCommon Stock | 28,280 | $29.74 | $841,047.20 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 2 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,780.5533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 23:01 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
SaleCommon Stock | 72,895 | $54.45 | $3,969,307.70 |
DisclosureSEC source: 0001209191-13-012161 · doc4.xml · nonDerivative · entry 1 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,500.5533 F1 · price: This transaction was executed in multiple trades ranging from $54.33 to $54.69 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 11, 2013 Filed Feb 12, 2013 22:04 UTC |
Sweere LoriEVP, Human Capital
|
Exercise / conversionStock Appreciation Rights · Derivative | 9,503 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001209191-13-008081 · doc4.xml · derivative · entry 5 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,503 Underlying: Common Stock · 9,503 shares Expires 2020-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock appreciation rights vest at a rate of 25% annually on February 9 from the years 2011 through 2014. Read SEC document |
| February 11, 2013 Filed Feb 12, 2013 22:04 UTC |
Sweere LoriEVP, Human Capital
|
SaleCommon Stock | 1,650 | $57.42 | $94,746.30 |
DisclosureSEC source: 0001209191-13-008081 · doc4.xml · nonDerivative · entry 4 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,450.8754 Read SEC document |
| February 11, 2013 Filed Feb 12, 2013 22:04 UTC |
Sweere LoriEVP, Human Capital
|
Tax withholdingCommon Stock | 7,027 | $57.74 | $405,738.98 |
DisclosureSEC source: 0001209191-13-008081 · doc4.xml · nonDerivative · entry 3 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,100.8754 Read SEC document |
| February 11, 2013 Filed Feb 12, 2013 22:04 UTC |
Sweere LoriEVP, Human Capital
|
Exercise / conversionCommon Stock | 9,503 | $33.00 | $313,599.00 |
DisclosureSEC source: 0001209191-13-008081 · doc4.xml · nonDerivative · entry 2 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,127.8754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2013 Filed Feb 12, 2013 22:05 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Tax withholdingCommon Stock | 2,546 | $57.74 | $147,006.04 |
DisclosureSEC source: 0001209191-13-008073 · doc4.xml · nonDerivative · entry 1 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,395.5533 Read SEC document |
| February 08, 2013 Filed Feb 12, 2013 22:02 UTC |
HEMSLEY STEPHEN JDirector · President & Chief Exec Officer
|
Tax withholdingCommon Stock | 4,716 | $57.74 | $272,301.84 |
DisclosureSEC source: 0001209191-13-008075 · doc4.xml · nonDerivative · entry 1 HEMSLEY STEPHEN J · CIK 0001180162 · Director · President & Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,622,138.5923 Read SEC document |
| February 08, 2013 Filed Feb 12, 2013 22:02 UTC |
RANGEN ERIC SSr VP & Chief Acctg Officer
|
Tax withholdingCommon Stock | 633 | $57.74 | $36,549.42 |
DisclosureSEC source: 0001209191-13-008078 · doc4.xml · nonDerivative · entry 1 RANGEN ERIC S · CIK 0001175737 · Sr VP & Chief Acctg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,763.555 Read SEC document |
| February 08, 2013 Filed Feb 12, 2013 22:03 UTC |
RENFRO LARRY CEVP, UHG and CEO, Optum
|
Tax withholdingCommon Stock | 3,576 | $57.74 | $206,478.24 |
DisclosureSEC source: 0001209191-13-008079 · doc4.xml · nonDerivative · entry 1 RENFRO LARRY C · CIK 0001235046 · EVP, UHG and CEO, Optum 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,174.043 Read SEC document |
| February 08, 2013 Filed Feb 12, 2013 22:04 UTC |
Sweere LoriEVP, Human Capital
|
Tax withholdingCommon Stock | 1,273 | $57.74 | $73,503.02 |
DisclosureSEC source: 0001209191-13-008081 · doc4.xml · nonDerivative · entry 1 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,624.8754 Read SEC document |
| February 08, 2013 Filed Feb 12, 2013 22:04 UTC |
WICHMANN DAVID SEVP & CFO, Pres UHG Operations
|
Tax withholdingCommon Stock | 2,546 | $57.74 | $147,006.04 |
DisclosureSEC source: 0001209191-13-008082 · doc4.xml · nonDerivative · entry 1 WICHMANN DAVID S · CIK 0001268489 · EVP & CFO, Pres UHG Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,915.4933 Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:33 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
GrantNon-Qualified Stock Options (right to buy) · Derivative | 59,587 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001209191-13-007393 · doc4.xml · derivative · entry 2 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,587 Underlying: Common Stock · 59,587 shares Expires 2023-02-06 F3 · derivative.exercise_date: The non-qualified stock options vest at a rate of 25% annually on February 6 from the years 2014 through 2017. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:33 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
GrantCommon Stock | 19,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-007393 · doc4.xml · nonDerivative · entry 1 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,941.5533 F1 · shares: The restricted stock units will vest at a rate of 25% annually on February 6 from the years 2014 through 2017. F2 · balance_after: Amount does not include performance-based restricted stock units granted to the executive officer on February 6, 2013, as performance awards not tied to stock price are not derivative securities for purposes of Section 16 under guidance from the staff of the SEC. The number of performance-based restricted stock units that the executive officer will receive will be determined at the end of the 3-year performance period and will be dependent upon the achievement of cumulative 3-year EPS and average return-on-equity performance metrics approved by the Compensation and Human Resources Committee. The target number of performance-based restricted stock units is 39,213. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:33 UTC |
HEMSLEY STEPHEN JDirector · President & Chief Exec Officer
|
GrantNon-Qualified Stock Options (right to buy) · Derivative | 99,312 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001209191-13-007395 · doc4.xml · derivative · entry 3 HEMSLEY STEPHEN J · CIK 0001180162 · Director · President & Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,312 Underlying: Common Stock · 99,312 shares Expires 2023-02-06 F3 · derivative.exercise_date: The non-qualified stock options vest at a rate of 25% annually on February 6 from the years 2014 through 2017. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:33 UTC |
HEMSLEY STEPHEN JDirector · President & Chief Exec Officer
|
GrantCommon Stock | 32,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-007395 · doc4.xml · nonDerivative · entry 1 HEMSLEY STEPHEN J · CIK 0001180162 · Director · President & Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,626,854.5923 F1 · shares: The restricted stock units will vest at a rate of 25% annually on February 6 from the years 2014 through 2017. F2 · balance_after: Amount does not include performance-based restricted stock units granted to the executive officer on February 6, 2013, as performance awards not tied to stock price are not derivative securities for purposes of Section 16 under guidance from the staff of the SEC. The number of performance-based restricted stock units that the executive officer will receive will be determined at the end of the 3-year performance period and will be dependent upon the achievement of cumulative 3-year EPS and average return-on-equity performance metrics approved by the Compensation and Human Resources Committee. The target number of performance-based restricted stock units is 65,354. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:34 UTC |
RANGEN ERIC SSr VP & Chief Acctg Officer
|
GrantNon-Qualified Stock Options (right to buy) · Derivative | 13,242 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001209191-13-007397 · doc4.xml · derivative · entry 2 RANGEN ERIC S · CIK 0001175737 · Sr VP & Chief Acctg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,242 Underlying: Common Stock · 13,242 shares Expires 2023-02-06 F3 · derivative.exercise_date: The non-qualified stock options vest at a rate of 25% annually on February 6 from the years 2014 through 2017. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:34 UTC |
RANGEN ERIC SSr VP & Chief Acctg Officer
|
GrantCommon Stock | 4,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-007397 · doc4.xml · nonDerivative · entry 1 RANGEN ERIC S · CIK 0001175737 · Sr VP & Chief Acctg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,396.555 F1 · shares: The restricted stock units will vest at a rate of 25% annually on February 6 from the years 2014 through 2017. F2 · balance_after: Amount does not include performance-based restricted stock units granted to the executive officer on February 6, 2013, as performance awards not tied to stock price are not derivative securities for purposes of Section 16 under guidance from the staff of the SEC. The number of performance-based restricted stock units that the executive officer will receive will be determined at the end of the 3-year performance period and will be dependent upon the achievement of cumulative 3-year EPS and average return-on-equity performance metrics approved by the Compensation and Human Resources Committee. The target number of performance-based restricted stock units is 8,714. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:34 UTC |
RENFRO LARRY CEVP, UHG and CEO, Optum
|
GrantNon-Qualified Stock Options (right to buy) · Derivative | 59,587 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001209191-13-007398 · doc4.xml · derivative · entry 2 RENFRO LARRY C · CIK 0001235046 · EVP, UHG and CEO, Optum 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,587 Underlying: Common Stock · 59,587 shares Expires 2023-02-06 F3 · derivative.exercise_date: The non-qualified stock options vest at a rate of 25% annually on February 6 from the years 2014 through 2017. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:34 UTC |
RENFRO LARRY CEVP, UHG and CEO, Optum
|
GrantCommon Stock | 19,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-007398 · doc4.xml · nonDerivative · entry 1 RENFRO LARRY C · CIK 0001235046 · EVP, UHG and CEO, Optum 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,750.043 F1 · shares: The restricted stock units will vest at a rate of 25% annually on February 6 from the years 2014 through 2017. F2 · balance_after: Amount does not include performance-based restricted stock units granted to the executive officer on February 6, 2013, as performance awards not tied to stock price are not derivative securities for purposes of Section 16 under guidance from the staff of the SEC. The number of performance-based restricted stock units that the executive officer will receive will be determined at the end of the 3-year performance period and will be dependent upon the achievement of cumulative 3-year EPS and average return-on-equity performance metrics approved by the Compensation and Human Resources Committee. The target number of performance-based restricted stock units is 39,213. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:35 UTC |
SHORT MARIANNE DEVP & Chief Legal Officer
|
GrantNon-Qualified Stock Options (right to buy) · Derivative | 52,967 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001209191-13-007399 · doc4.xml · derivative · entry 2 SHORT MARIANNE D · CIK 0001565456 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,967 Underlying: Common Stock · 52,967 shares Expires 2023-02-06 F3 · derivative.exercise_date: The non-qualified stock options vest at a rate of 25% annually on February 6 from the years 2014 through 2017. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:35 UTC |
SHORT MARIANNE DEVP & Chief Legal Officer
|
GrantCommon Stock | 34,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-007399 · doc4.xml · nonDerivative · entry 1 SHORT MARIANNE D · CIK 0001565456 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,856 F1 · shares: The restricted stock units will vest at a rate of 25% annually on February 6 from the years 2014 through 2017. F2 · balance_after: Amount does not include performance-based restricted stock units granted to the executive officer on February 6, 2013, as performance awards not tied to stock price are not derivative securities for purposes of Section 16 under guidance from the staff of the SEC. The number of performance-based restricted stock units that the executive officer will receive will be determined at the end of the 3-year performance period and will be dependent upon the achievement of cumulative 3-year EPS and average return-on-equity performance metrics approved by the Compensation and Human Resources Committee. The target number of performance-based restricted stock units is 17,428. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:36 UTC |
Sweere LoriEVP, Human Capital
|
GrantNon-Qualified Stock Options (right to buy) · Derivative | 26,484 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001209191-13-007400 · doc4.xml · derivative · entry 2 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,484 Underlying: Common Stock · 26,484 shares Expires 2023-02-06 F3 · derivative.exercise_date: The non-qualified stock options vest at a rate of 25% annually on February 6 from the years 2014 through 2017. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:36 UTC |
Sweere LoriEVP, Human Capital
|
GrantCommon Stock | 8,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-007400 · doc4.xml · nonDerivative · entry 1 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,897.8754 F1 · shares: The restricted stock units will vest at a rate of 25% annually on February 6 from the years 2014 through 2017. F2 · balance_after: Amount does not include performance-based restricted stock units granted to the executive officer on February 6, 2013, as performance awards not tied to stock price are not derivative securities for purposes of Section 16 under guidance from the staff of the SEC. The number of performance-based restricted stock units that the executive officer will receive will be determined at the end of the 3-year performance period and will be dependent upon the achievement of cumulative 3-year EPS and average return-on-equity performance metrics approved by the Compensation and Human Resources Committee. The target number of performance-based restricted stock units is 17,428. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:36 UTC |
WICHMANN DAVID SEVP & CFO, Pres UHG Operations
|
GrantNon-Qualified Stock Options (right to buy) · Derivative | 59,587 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001209191-13-007402 · doc4.xml · derivative · entry 3 WICHMANN DAVID S · CIK 0001268489 · EVP & CFO, Pres UHG Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,587 Underlying: Common Stock · 59,587 shares Expires 2023-02-06 F3 · derivative.exercise_date: The non-qualified stock options vest at a rate of 25% annually on February 6 from the years 2014 through 2017. Read SEC document |
| February 06, 2013 Filed Feb 8, 2013 21:36 UTC |
WICHMANN DAVID SEVP & CFO, Pres UHG Operations
|
GrantCommon Stock | 19,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-007402 · doc4.xml · nonDerivative · entry 1 WICHMANN DAVID S · CIK 0001268489 · EVP & CFO, Pres UHG Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,461.4933 F1 · shares: The restricted stock units will vest at a rate of 25% annually on February 6 from the years 2014 through 2017. F2 · balance_after: Amount does not include performance-based restricted stock units granted to the executive officer on February 6, 2013, as performance awards not tied to stock price are not derivative securities for purposes of Section 16 under guidance from the staff of the SEC. The number of performance-based restricted stock units that the executive officer will receive will be determined at the end of the 3-year performance period and will be dependent upon the achievement of cumulative 3-year EPS and average return-on-equity performance metrics approved by the Compensation and Human Resources Committee. The target number of performance-based restricted stock units is 39,213. Read SEC document |
| February 04, 2013 Filed Feb 5, 2013 22:26 UTC |
Sweere LoriEVP, Human Capital
|
Exercise / conversionStock Appreciation Rights · Derivative | 14,140 | $0.00 Strike: $29.74 | $0.00 |
DisclosureSEC source: 0001209191-13-006570 · doc4.xml · derivative · entry 5 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,140 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock appreciation rights vested at a rate of 25% annually on February 3 from the years 2010 through 2013. Read SEC document |
| February 04, 2013 Filed Feb 5, 2013 22:26 UTC |
Sweere LoriEVP, Human Capital
|
SaleCommon Stock | 4,382 | $55.67 | $243,945.94 |
DisclosureSEC source: 0001209191-13-006570 · doc4.xml · nonDerivative · entry 4 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,183.8754 Read SEC document |
| February 04, 2013 Filed Feb 5, 2013 22:26 UTC |
Sweere LoriEVP, Human Capital
|
Tax withholdingCommon Stock | 9,758 | $55.75 | $544,008.50 |
DisclosureSEC source: 0001209191-13-006570 · doc4.xml · nonDerivative · entry 3 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,565.8754 Read SEC document |
| February 04, 2013 Filed Feb 5, 2013 22:26 UTC |
Sweere LoriEVP, Human Capital
|
Exercise / conversionCommon Stock | 14,140 | $29.74 | $420,523.60 |
DisclosureSEC source: 0001209191-13-006570 · doc4.xml · nonDerivative · entry 2 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,323.8754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2013 Filed Feb 5, 2013 22:24 UTC |
BOUDREAUX GAILEVP & CEO, UnitedHealthcare
|
Tax withholdingCommon Stock | 3,229 | $55.77 | $180,081.33 |
DisclosureSEC source: 0001209191-13-006558 · doc4.xml · nonDerivative · entry 1 BOUDREAUX GAIL · CIK 0001287920 · EVP & CEO, UnitedHealthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,334.5533 Read SEC document |
| February 01, 2013 Filed Feb 5, 2013 22:24 UTC |
HEMSLEY STEPHEN JDirector · President & Chief Exec Officer
|
Tax withholdingCommon Stock | 4,508 | $55.77 | $251,411.16 |
DisclosureSEC source: 0001209191-13-006562 · doc4.xml · nonDerivative · entry 1 HEMSLEY STEPHEN J · CIK 0001180162 · Director · President & Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,594,177.5923 Read SEC document |
| February 01, 2013 Filed Feb 5, 2013 22:25 UTC |
RANGEN ERIC SSr VP & Chief Acctg Officer
|
Tax withholdingCommon Stock | 811 | $55.77 | $45,229.47 |
DisclosureSEC source: 0001209191-13-006566 · doc4.xml · nonDerivative · entry 1 RANGEN ERIC S · CIK 0001175737 · Sr VP & Chief Acctg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,039.555 F1 · balance_after: Includes shares received through UnitedHealth Group Incorporated's Employee Stock Purchase Plan. Read SEC document |
| February 01, 2013 Filed Feb 5, 2013 22:25 UTC |
RENFRO LARRY CEVP, UHG and CEO, Optum
|
Tax withholdingCommon Stock | 9,958 | $55.77 | $555,357.66 |
DisclosureSEC source: 0001209191-13-006568 · doc4.xml · nonDerivative · entry 1 RENFRO LARRY C · CIK 0001235046 · EVP, UHG and CEO, Optum 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,143.043 Read SEC document |
| February 01, 2013 Filed Feb 5, 2013 22:26 UTC |
Sweere LoriEVP, Human Capital
|
Tax withholdingCommon Stock | 1,640 | $55.77 | $91,462.80 |
DisclosureSEC source: 0001209191-13-006570 · doc4.xml · nonDerivative · entry 1 Sweere Lori · CIK 0001407932 · EVP, Human Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,183.8754 F1 · balance_after: Includes shares received through UnitedHealth Group Incorporated's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.